Optimal timing for ctDNA assessment to detect molecular residual disease after definitive chemoradiotherapy in locally advanced head and neck cancer

A multicenter prospective study evaluated the diagnostic performance, prognostic value, and optimal timing of circulating tumor DNA (ctDNA) assessment for molecular residual disease (MRD) detection after definitive chemoradiotherapy (CRT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Seventy-four patients were enrolled. Plasma samples were collected before treatment, at 8 and 12 weeks after CRT, and during follow-up. ctDNA was analyzed using a plasma-only methylation-based assay. Baseline ctDNA was dectable in 85.1% of patients. Among post-treatment timepoints, week-12 ctDNA showed the highest diagnostic accuracy for recurrence detection, with 69% sensitivity, 100% specificity, 100% positive predictive value, and 76% negative predictive value. Detectable week-12 ctDNA was associated with shorter progression-free survival (HR 6.44; 95% CI 2.73-16.74) and overall survival (7.31; 2.80-22.31). Longitudinal ctDNA surveillance identified additional recurrences among patients with undetectable week-12 ctDNA. Exploratory analyses integrating PET/CT and ctDNA identified prognostically distinct PFS groups (log-rank p=0.033), with the greatest additional prognostic stratification observed among PET partial responders. The authors conclude that plasma-only methylation-based ctDNA provided high-specificity prognostic information after definitive CRT in LA-HNSCC, particularly at week 12 and in PET partial responders.